Skip to main content

Rheumatoid Arthritis

Inflammation,reflex,neural

Inflammatory Arthritis Spread by ATP and Neural Crosstalk

May 19, 2022

A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk. Such findings may be important in disorders like rheumatoid arthritis (RA)

Read Article
morbidity,covid,heart,lung,brain

Multimorbidity Burden in Rheumatoid Arthritis

May 17, 2022

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.



This population-based study examined prevalent RA as of January 2015 and sought to

Read Article
ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf
Dr. John Cush @RheumNow( View Tweet )
May 16, 2022
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

May 12, 2022

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an

Read Article
Early inflammatory arthritis pts (n=35,807; 86% White & 5,164 ethnic minority). Whites & minorities were equally seen by rheum <3 wks & started on Rx < 6wks, <inorities had less remission @3 mos (OR 0.79) or recv MTX 1st or steroids(0.68-0.63) https://t.co/rK7GLt5n1X https://t.co/uUwBBCnyGL
Dr. John Cush @RheumNow( View Tweet )
May 12, 2022
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it?https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3
Dr. John Cush @RheumNow( View Tweet )
May 12, 2022
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

May 10, 2022

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 



The study

Read Article
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!

Peter Nash @drpnash( View Tweet )

May 10, 2022
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA
Dr. John Cush @RheumNow( View Tweet )
May 10, 2022
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritishttps://t.co/5dXe0AdNzE https://t.co/eS4KdaKBmC
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
An increasing incidence of RA is driven by increasing # of ACPA-negative RA (but not ACPA-positive RA), partly explained by an ageing population (thus making ACPA-negative RA more prevalent in coming years) https://t.co/9vC8aCphKc

Dr. John Cush @RheumNow( View Tweet )

May 07, 2022
Trends in RA Disability, Despite Biologics Disability claims in the U.S. related to RA were just as common in 2015 as in 1999, a gov't researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.https://t.co/vyyjTbkLN2 https://t.co/D5Eo42P4cw
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
Study of 17 homeless RA or PsA pts - less clinic access (80% vs 91%), more ED use (20 vs 5), less DMARDs (43% vs 100%), more steroids (29% vs 0%); 83% unable to work due to health. Greatest need - dental , PT, knee surgery, employment & housing https://t.co/VHnTR0MTkr https://t.co/JDZTELz2qB
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
medical.marijuana

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain

Creaky Joints
May 06, 2022

A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and

Read Article
There is 1.4 million transgender persons in the US. ACP has published a guideline "Care of the Transgender Patient" addressing health disparities, certain cancers, substance abuse, mental health conditions, infections, and chronic diseases. https://t.co/AoBeOzv9YH https://t.co/jKabVELPxH
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritishttps://t.co/n1O4g4HpMM https://t.co/ulF1d2gDkG
Dr. John Cush @RheumNow( View Tweet )
May 05, 2022
Did you miss last night's TNR on RA, improving future therapy? We've got you covered. Listen to the playback here.https://t.co/ci6TZOw3VX https://t.co/31gRUaKbQm
Dr. John Cush @RheumNow( View Tweet )
May 04, 2022
DMARDs,biologics,RA

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

May 04, 2022

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Read Article
Neural networks of high-res quantitative CT (HR-pQCT) scans allowed for 3D imaging of MCP2 to differentiate normals from #RA & #PsA. 932 of 617 ppts correct AuROC for HC 82%, RA 75%, PsA 68%. UA pts read as 86% RA,11% PsA, & 3% HC https://t.co/wSQgllYgug https://t.co/yA6g55SpeC
Dr. John Cush @RheumNow( View Tweet )
May 04, 2022
RA, hands, MCP, deformity

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

MedPage Today
May 03, 2022

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.



Over that 17-year period, rates of Medicare

Read Article
Rheumatologic diagnosis through hand exam by Dr. Sarah Chung @ACPinternists #rheumatology #rheumtwitter #MedEd #rheumatoidarthritis #BJHM #Hospitalmedicine #IM2022 #MedTwitter 👇🏽 https://t.co/qR4zNa4NcX
Brown Journal of Hospital Medicine @BrownJHM( View Tweet )
May 03, 2022
Leflunomide responses in #RA assoc w/ high metabolite levels (A77 1726). In 115 LEF Rx Pts, 40% had LDAS/remission. A77 1726 levels neg correlation w/ DAS28-ESR (r = − 0.42, p < 0.001). Levels >10µg/mL & LDAS PPV 70%; NPV 93% https://t.co/V32wUGVWLM https://t.co/L9DwZBwet9
Dr. John Cush @RheumNow( View Tweet )
May 02, 2022
Study of 33 #RA pts finds nearly half had peripheral neuropathy (48.5%); sensorimotor in 64.7%, motor in 17.6%. Neuropathy was NOT associated with age, gender, disease activity, functionality, or falls https://t.co/r2aQI2cm27 https://t.co/OOQlWkCAft
Dr. John Cush @RheumNow( View Tweet )
May 02, 2022
×